Puma Biotechnology Inc., a biopharmaceutical company based in Los Angeles, reported a weak third-quarter.

The company reported a net loss of $60.4 million, or -$1.87 a share, for the third quarter, compared to a loss of $35.9 million, or -$1.19 a share, in the same quarter last year. Analysts had given the company’s shares a consensus estimate of $1.84 a share.

On Tuesday, the company’s shares closed down 11 percent to $80.69.